Neos Therapeutics (NEOS) Getting Somewhat Critical Press Coverage, Study Shows
Media headlines about Neos Therapeutics (NASDAQ:NEOS) have been trending somewhat negative recently, according to Alpha One Sentiment. Alpha One, a division of Accern, identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neos Therapeutics earned a coverage optimism score of -0.06 on Alpha One’s scale. Alpha One also gave media coverage about the company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an impact on the company’s share price in the immediate future.
Several analysts recently issued reports on the company. Zacks Investment Research downgraded Neos Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, June 10th. ValuEngine raised Neos Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, May 18th. Cowen and Company assumed coverage on Neos Therapeutics in a report on Wednesday, April 5th. They issued an “outperform” rating and a $20.00 price target on the stock. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $15.00 price target on shares of Neos Therapeutics in a report on Saturday, March 11th.
Shares of Neos Therapeutics (NASDAQ NEOS) opened at 8.65 on Friday. The company’s market cap is $195.14 million. Neos Therapeutics has a one year low of $4.85 and a one year high of $10.73. The company has a 50 day moving average price of $7.79 and a 200 day moving average price of $6.81.
Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings data on Tuesday, May 9th. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.07. Neos Therapeutics had a negative return on equity of 512.10% and a negative net margin of 719.86%. The company had revenue of $5.63 million for the quarter. Equities research analysts expect that Neos Therapeutics will post ($3.23) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This article was originally published by Financial Market News and is the sole property of of Financial Market News. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.financial-market-news.com/2017/06/17/neos-therapeutics-neos-getting-somewhat-critical-press-coverage-study-shows.html.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.